Position in EOLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Derivatives in EOLS
reported options exposure · as of Jun 30, 2026CallValue
$1,388,000
CallShares
200,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $36,596,582 across 6 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
52,989 | $28,711,029 | |
| 2 | BIOA |
BioAge Labs, Inc.
|
146,334 | $3,586,646 | |
| 3 | INDV |
Indivior Pharmaceuticals, Inc.
|
67,512 | $2,770,017 | |
| 4 | XERS |
Xeris Biopharma Holdings, Inc.
|
132,746 | $1,051,348 | |
| 5 | AYTU |
Aytu Biopharma, Inc
|
148,546 | $319,373 | |
| 6 | TLPH |
Talphera, Inc.
|
153,563 | $158,169 |
All Filings in EOLS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,388,000 | 200,000 | Call | Sole | 2026-08-14 | |
| 2026-03-31 | $514,572 | 125,200 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $790,020 | 118,800 | Call | Sole | 2026-02-17 | |
| 2025-03-31 | $601,500 | 50,000 | Put | Sole | 2025-05-15 | |
| 2024-12-31 | $1,075,549 | 97,423 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||